Science
Clinical Trials
Kalson Biotech is committed to the development of DSAR TTM therapies for cancer. Successful clinical trials are required to gain regulatory approval for new medications to advance patient care and may be required to support any approved products.
A list of existing Kalson Biotech clinical trials are below. For more information on Kalson Biotech clinical trials that may be recruiting, search “Kalson Biotech ” at www.clinicaltrials.gov.
Program
DSART-501
Phase
1
Sponsor
Kalson Biotech
Indication
The ALPHA Trial: Relapsed or refractory non-Hodgkin lymphoma (NHL)
Program
DSART-715
Phase
1
Sponsor
Kalson Biotech
Indication
The UNIVERSAL Trial: Relapsed or refractory multiple myeloma (MM)
Program
DSBT42
Phase
1
Sponsor
Servier
Indication
The PALL Trial: Relapsed or refractory Acute lymphoblastic leukemia (ALL) in pediatric patients
Program
DSBT42
Phase
1
Sponsor
Servier
Indication
The CALM Trial: Relapsed or refractory ALL in adults
Kalson Biotech ’s Expanded Access Policy
Kalson Biotech does not currently have any active Expanded Access protocols but we do have Clinical Trials open. These can be found on ClinicalTrials.gov.
Treating physicians may request information about Expanded Access for an Kalson Biotech therapy by contacting our clinical trials team by phone or email at:
- +1 (782) 820 3934
- clinicaltrials@kalsonbiotech.com
Kalson Biotech will evaluate these requests individually and may provide physician requested Expanded Access for an Kalson Biotech therapy for patients with no other available therapies and for patients who are not eligible to participate in a current Kalson Biotech clinical trial. Kalson Biotech will acknowledge receipt of the request via telephone call or email within 5 business days of receipt of the request.
Pursuant to the 21st Century Cures Act: the posting of policies by manufacturers and distributors shall not serve as a guarantee of access to any specific investigational therapy by any individual patient.